On Wednesday, August 1st, FDA released a notice with updated prescription drug user fee rates for fiscal year 2019.
According to the Food, Drug, & Cosmetic (FD&C) Act, application fees should provide 20% of the total revenue, while program fees should provide the other 80%. Application fees are set at $202,064,400 for FY 2019. The application fees were determined by estimating the total number of expected fee-paying full application equivalents (FAEs) for the year. The updated fees are as follows:
This is a 6.9% increase from FY 2018 fees, which were $2,421,495 per full application requiring clinical data, and $1,210,748 per application not requiring clinical data.
FY 2019 program fees were calculated by dividing the adjusted total revenue from program fees ($808,257,600) by the estimated number of program fees (2,608). The FY 2019 program fee is $309,915. This is a 1.9 percent increase from the FY 2018 program fee of $304,162.
|Fee Category||FY 2019 Fee Rates||FY 2018 Fee Rates|
|Application Requiring Clinical Data||$2,588,478||$2,421,495|
|Application Not Requiring Clinical Data||$1,294,239||$1,210,748|
August 8, 2018
On Tuesday, July 31st, FDA released a notice with updated biosimilar user fee rates for fiscal year 2019. The base revenue for FY 2019 is $40,214,000, not adjusted for inflation or operating...
August 2, 2016
The Prescription Drug User Fee Amendments of 2012 (PDUFA V) allows FDA to collect user fees for the review of applications concerning human drug and biological products, the establishments where...
August 7, 2015
As amended by the Prescription Drug User Fee Amendments of 2012, The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to assess and collect fees from sponsors submitting applications...